BeiGene, SpringWorks form MapKure to develop BRAF inhibitor

Nine months after partnering to test a BRAF-MEK combination therapy, BeiGene and Pfizer spinout SpringWorks are collaborating again, this time forming a joint venture to develop a BeiGene BRAF inhibitor that could lead to combination therapies with SpringWorks' MEK inhibitor PD-0325901.

MapKure LLC gained an exclusive license from BeiGene Ltd. (NASDAQ:BGNE; HKEX:06160) to develop and commercialize BGB-3245 in Japan and outside of Asia. In return, BeiGene will hold a majority stake in the JV, and SpringWorks Therapeutics Inc. (New York, N.Y.) will contribute an equity investment. BeiGene retains China rights to the BRAF inhibitor and is eligible for milestones and royalties. Financial details are not disclosed. ...